RxDoctor Payments Data

Mohammed Almubarak, MD

General Practice · Morgantown, WVNPI 1013127638

Payments from drug & device makers

What this record shows

This record is dominated by education: $97 of the $114 with a category attached, or 85.2%. 4 manufacturers reported payments, led by AstraZeneca at 53.2% of the total. 2025 is the largest year on record at $60, 3.9 times the $15 reported in 2020. That places this record below the midpoint for general practice clinicians in WV, where the typical reported total is $219.

$114in general payments, 2019–2025

Across 5 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$60
  • Mirati Therapeutics, Inc.$21
  • Seagen Inc.$17
  • E.r. Squibb & Sons, L.L.C.$15
$1,735,318in research payments, 2019–2025

Across 128 payments — averaging $13,557 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$591K
  • Merck$455K
  • Dynavax Technologies Corporation$428K
  • E.r. Squibb & Sons, L.L.C.$58K
  • AstraZeneca$55K
  • GSK$52K
  • plus $97K from 4 others

What the payments were for

  • Food & beverage$1715%
  • Education$9785%

General payments by program year

20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$114 in reported general payments places this provider in the 30th percentile of 437 general practice providers in West Virginia.

See all general practice providers in West Virginia

Medicare billing

Part B allowed, 2024
$107,656
Medicare patients
248
Services billed
865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate89$1,453,448
RozlytrekEntrectinib12$354,356
LumakrasSotorasib12$253,447
GavretoPralsetinib12$82,457
Prochlorperazine Maleate36$446
Dexamethasone28$400
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$342
Ondansetron Hcl38$341
Hydroxyurea30$314
Prednisone23$177
Methylprednisolone13$94
Doxycycline Hyclate14$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$60$1,453,44889 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 437 general practice providers in West Virginia.

Other general practice in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →